Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amicus Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Amicus Therapeutics, Inc.’s stock price such as:

• Amicus Therapeutics, Inc.’s current stock price and volume
• Why Amicus Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for FOLD from analysts
• FOLD’s stock price momentum as measured by its relative strength

About Amicus Therapeutics, Inc. (FOLD)

Before we jump into Amicus Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Want to learn more about Amicus Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amicus Therapeutics, Inc..

Amicus Therapeutics, Inc.’s Stock Price as of Market Close

As of March 06, 2024, 4:00 PM, CST, Amicus Therapeutics, Inc.’s stock price was $12.60.

Amicus Therapeutics, Inc. is down 5.62% from its previous closing price of $13.35.

During the last market session, Amicus Therapeutics, Inc.’s stock traded between $13.19 and $13.53. Currently, there are 300.72 million shares of Amicus Therapeutics, Inc. stock available for purchase.

Unfortunately, Amicus Therapeutics, Inc.’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Amicus Therapeutics, Inc. Stock Price History

Amicus Therapeutics, Inc.’s (FOLD) price is currently down 1.72% so far this month.

During the month of March, Amicus Therapeutics, Inc.’s stock price has reached a high of $13.60 and a low of $12.37.

Over the last year, Amicus Therapeutics, Inc. has hit prices as high as $14.57 and as low as $9.70. Year to date, Amicus Therapeutics, Inc.’s stock is up 3.19%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amicus Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 05, 2024, there were 4 analysts who downgraded Amicus Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amicus Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amicus Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amicus Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amicus Therapeutics, Inc. (FOLD) by visiting AAII Stock Evaluator.

Relative Price Strength of Amicus Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 05, 2024, Amicus Therapeutics, Inc. has a weighted four-quarter relative price strength of -0.63%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Amicus Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amicus Therapeutics, Inc. Stock Price: Bottom Line

As of March 6, 2024, Amicus Therapeutics, Inc.’s stock price is $12.60, which is down 5.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amicus Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.